StockNews.AISignal intelligence
Summit Therapeutics Inc. · NASDAQ · Healthcare
Browse public SMMT signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Akeso's Phase 3 HARMONi-2 shows ivonescimab monotherapy improving OS versus Keytruda in Chinese NSCLC, with a PFS HR of 0.51. China granted ivonescimab marketing authorization in April 2025, though Summit's global status remains investigational. A conference presentation could catalyze licensing talks or strategic discussions for SMMT.
View signal analysisSummit Therapeutics (SMMT) reported a narrower-than-expected Q2 loss but warned it lacks sufficient working capital for 12 months of planned operations, signaling a near-term funding hurdle. Jim Cramer described SMMT as a 'great spec,' potentially boosting sentiment despite liquidity concerns. The outcome could drive volatility until financing or partnership news materializes.
View signal analysisSummit reported Q2 results with $690.7M cash and ATM proceeds totaling $299.2M, extending financing runway. ASCO readouts for HARMONi-6 and updated HARMONi OS show cross-population survival benefits, and the FDA accepted the ivonescimab BLA with a PDUFA of 11/14/2026, creating near-term catalysts. A complete HARMONi-3 readout and continued international development support upside.
View signal analysisUpdated HARMONi data show stronger survival signals for Western patients (HR 0.76) with longer follow-up and no new safety issues. The trial supports Summit's FDA Biologics License Application, with a target action date of November 14, 2026. A positive decision could be a meaningful near-term catalyst for SMMT.
View signal analysisSummit reported updated global HARMONi OS analyses for ivonescimab in EGFR-mut NSCLC after third-gen TKIs. Western HR 0.76 aligns with Asian results, boosting OS signal. FDA accepted the BLA with a 11/14/2026 PDUFA date, underscoring potential near- to mid-term regulatory and commercial upside for SMMT.
View signal analysisSummit Therapeutics and Akeso reported Phase II AK112-206 results in first-line MSS metastatic colorectal cancer showing an ORR of 70.8% and a DCR of 100% when ivonescimab is combined with mFOLFOX6. The 20 mg/kg dose delivered more durable responses, with a 9-month PFS of 76.1% and a DOR of 79.1%. Safety remains manageable, with 20.4% serious TRAEs and no ivonescimab-related deaths, supporting further Phase III exploration via HARMONi-GI3.
View signal analysis